| Juvenile polyarthritis
Hadlima vs Rasuvo
Side-by-side clinical, coverage, and cost comparison for juvenile polyarthritis.Deep comparison between: Hadlima vs Rasuvo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRasuvo has a higher rate of injection site reactions vs Hadlima based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rasuvo but not Hadlima, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hadlima
Rasuvo
At A Glance
SC injection
Every other week
TNF-alpha blocker
SC injection
Once weekly
Folate analog metabolic inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Psoriasis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile polyarthritis SC every other week based on weight for patients 2 years and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg).
Crohn Disease Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction (80 or 160 mg Day 1, 40 or 80 mg Day 15), then 20 or 40 mg every other week starting Day 29.
Ulcerative Colitis 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis vulgaris, Uveitis 80 mg initial dose, then 40 mg every other week starting 1 week after the initial dose.
Hidradenitis Suppurativa 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Rheumatoid Arthritis 7.5 mg SC once weekly as starting dose; adjust gradually to achieve optimal response; doses greater than 20 mg/wk associated with increased serious toxicity; available doses 7.5-30 mg in 2.5 mg increments.
Juvenile polyarthritis 10 mg/m2 SC once weekly as starting dose; adjust gradually to achieve optimal response.
Psoriasis 10-25 mg SC once weekly as starting dose; adjust gradually; do not ordinarily exceed 30 mg/week; reduce to lowest effective dose and longest possible rest period once optimal response achieved.
Contraindications
—
- Pregnancy
- Alcoholism, alcoholic liver disease, or other chronic liver disease
- Overt or laboratory evidence of immunodeficiency syndromes
- Preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia
- Known hypersensitivity to methotrexate
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, hyperlipidemia, flu syndrome, abdominal pain, laboratory test abnormalities.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Liver failure, hepatitis, autoimmune hepatitis, sarcoidosis, Merkel cell carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.
Most common (>=10%) Elevated liver function tests, nausea, vomiting
Serious Ulcerative stomatitis, leukopenia, hepatotoxicity, bone marrow suppression, interstitial pneumonitis, opportunistic infections, embryo-fetal toxicity, malignant lymphomas
Pharmacology
TNF-alpha blocker; adalimumab-bwwd is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Methotrexate is a folate analog metabolic inhibitor that inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair, and cellular replication; in rheumatoid arthritis the mechanism may involve immune function modulation, and in psoriasis it exploits the differential in epithelial cell proliferation rates.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hadlima
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Rasuvo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Hadlima
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (2/8) · Qty limit (2/8)
Rasuvo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Hadlima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Rasuvo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hadlima.
No savings programs available for Rasuvo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HadlimaView full Hadlima profile
RasuvoView full Rasuvo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.